HEPA filtered BMT ICU: High-level filtration, allowing only objects smaller than 0.2 microns to enter, crucial for protecting immunocompromised patients from bacteria and fungus.
T-Cell Depletion: With memory cell infusion, specifically targeting TCR alpha-beta cells, have improved transplant outcomes.
Improved Infection Management: Enhanced infection profiles & antibiotics usage have significantly reduced infection-related complications and mortality rates.
Haploidentical Transplants: Recent advancements enable successful BMT, where the body's immunity is intentionally suppressed, allowing for half-matched transplants.
Unrelated Donor Transplants: Even without a sibling match, blood disorder/ cancer can be treated through matching unrelated donor transplants or MUD transplants.
Peripheral Blood progenitor cell Collection: progenitor cell collection from peripheral blood, streamlining the process & reducing patient discomfort associated with harvest.
Reduced-Intensity Conditioning: For safer transplant procedures, particularly for older or medically fragile patients.
Integration of Immunotherapy: Has shown promising results in enhancing the body's immune response against cancer cells, potentially improving long-term outcomes.
Preventing Graft-versus-Host Disease (GVHD): Incorporating cutting-edge technologies to manage & reduce risk of complications which enhances the overall success of BMT.